Nouveautés dans les syndromes myélodysplasiques, Dr Mitja Nabergoj

1. Nouveautés diagnostiques et thérapeutiques dans les syndromes myélodysplasiques
2. Myelodysplastic syndromes (MDS)
3. Clinical presentation
4. Cytopenia as “sine qua non” criteria Dysplasia ≥ 10% ≥1 of bone marrow cell line <20% of blasts (threshold for AML)
5. Clinical presentation
6. Chromosomal abnormalities
7. CHIPa as a precursor state for hematological neoplasms
8. The New England Journal of Medicine
9. WHO 2016 classification of myeloid neoplasms and acute leukemia
10. Revised International Prognostic Scoring System (IPSS-R)
11. Implications of somatic mutations on prognosis
12. Treatment approach for MDS
13. Lower risk MDS (IPSS-R Very Low, Low et Intermediate with score ≤ 3.5)
14. Anemia in lower risk MDS
15. Blood transfusion = iron overload
16. Thrombocytopenia in lower risk MDS
17. Higher risk MDS
18. Non transplant-eligible high risk MDS: Hypometilating agents
19. To transplant, or not to transplant, that is the question…
20. Allogenic stem cell transplant: one size fits all?
21. New strategies for MDS patients
22. EPO-refractory anemia
23. Take home messages
24. Merci pour votre attention !

FINISH

SUBMIT

Title